MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, TCRX had $112K increase in cash & cash equivalents over the period. -$33,889K in free cash flow.

Cash Flow Overview

Change in Cash
$112K
Free Cash flow
-$33,889K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-35,710 -71,079
Depreciation expense
767 1,376
Accretion of marketable securities
-291 -2,063
Non-cash interest expense related to note payable
118 224
Stock-based compensation
3,011 6,687
Prepaid expenses and other assets
-867 489
Right-of-use assets and lease liabilities, net
463 2,355
Accounts payable
1,933 123
Accrued expense and other liabilities
-1,110 -2,741
Deferred revenue
-2,512 -5,246
Net cash used in operating activities
-32,464 -70,853
Purchases of property and equipment
1,425 2,811
Purchases of marketable securities
-1 87,472
Maturities of marketable securities
34,000 152,250
Net cash provided by (used in) investing activities
32,576 61,967
Proceeds from issuance of common stock under employee stock purchase plan
0 191
Cash paid for debt issuance costs
0 400
Cash paid for financing costs
0 200
Net cash provided by (used in) financing activities
0 -409
Net increase (decrease) in cash, cash equivalents and restricted cash
112 -9,295
Cash and cash equivalents at beginning of period
183,720 -
Cash and cash equivalents at end of period
174,537 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics, Inc. (TCRX)